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Abstract
Idiopathic pneumonia syndrome (IPS) is a non-infectious pulmonary complication after 
hematopoietic cell transplantation (HCT) and is difficult to diagnose. We evaluated six candidate 
proteins in plasma samples at day 7 after HCT and at onset of IPS from 41 IPS cases to identify 
potential IPS diagnostic or prognostic biomarkers. Samples at similar times from 162 HCT 
recipients without documented infections and 37 HCT recipients with respiratory viral pneumonia 
served as controls. In multivariable models, a combination of Stimulation-2 (ST2, OR 2.8; 
p<0.001) and Interleukin-6 (IL-6, OR 1.4; p=0.025) was the best panel to distinguish IPS at 
diagnosis from unaffected controls, while tumor necrosis factor receptor 1 (TNFR1, OR 2.9; 
p=0.002) was the best marker when comparing patients with IPS and viral pneumonia. The area 
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under the curve of the receiver operating characteristic (ROC) curves for discriminating between 
IPS and unaffected controls at day 7 post-HCT were 0.8 for ST2, 0.75 for IL-6, and 0.68 for 
TNFR1. Using estimated sensitivity and specificity values from cutoffs determined with the ROC 
analysis (cutoff level: ST2, 21 ng/mL; IL-6, 61 pg/mL; TNFR1 3421 pg/mL), we calculated 
positive predictive values (PPV) for a range of estimated population prevalence values of IPS. 
Among the three markers, ST2 showed the highest PPV for IPS occurrence. Based on an 8% 
assumed prevalence, a positive ST2 test increased likelihood of IPS to 50%. We conclude that a 
prospective validation study is warranted to determine whether a plasma biomarker panel can help 
with the non-invasive diagnosis and prognosis of IPS.
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INTRODUCTION
Idiopathic pneumonia syndrome (IPS) is a non-infectious pulmonary complication with 
diffuse lung injury after hematopoietic cell transplantation (HCT).1, 2 IPS develops in 4-12% 
of HCT recipients,3–7 and according to our recent study, the mortality rate by day 100 after 
IPS is as high as 70%.8 Current diagnostic criteria for IPS are widespread alveolar injury 
with symptoms and signs of pneumonia and no active lower respiratory tract infection.1, 2 In 
fact, our previous study showed that approximately half of the patients with previously 
diagnosed IPS had viral pathogens detected in bronchoalveolar lavage (BAL) samples, 
suggesting that distinguishing viral pneumonia from IPS is difficult if we use only clinical 
criteria.8 Although the evaluation of a BAL sample is necessary to diagnose IPS, the 
significance of detecting viral pathogen in the pathogenicity of pneumonia, especially with 
low viral load, is not necessarily clear, and bronchoscopic evaluation is occasionally 
unfeasible due to the patient conditions. Therefore, non-invasive blood tests that could aid in 
IPS diagnosis (an assay that accurately identifies patients at the onset of clinical disease) and 
prognosis (an assay that categorizes patients by degree of risk for disease occurrence) are 
required.9
Mortality after IPS remains high and the current standard treatment for IPS is high-dose 
corticosteroids. Although TNF-α receptor inhibitor is a promising drug, it has not been 
established for the treatment of IPS.10–12 Considering the high mortality rate, identification 
of IPS cases in the early phase of IPS for potential preemptive intervention might be critical.
Plasma biomarkers may be useful tools to support disease diagnosis, risk-stratify before the 
onset of clinical signs, or predict the outcomes because of the simplicity of sampling. No 
biomarkers for IPS have been identified so far. Based on previous reports, tumor necrosis 
factor receptor 1 (TNFR1) and interleukin-6 (IL-6) are candidate biomarkers for IPS since 
they were elevated in BAL samples from patients with IPS.10, 13 Stimulation 2 (ST2) can be 
a candidate considering that it is elevated in acute lung injury14–18 and an important 
biomarker of graft-versus-host disease (GVHD).19–25 Three other proteins (lymphocyte 
vessel endothelial receptor [LYVE], endothelial protein C receptor [EPCR], and herpes virus 
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entry mediator [HVEM]) were selected as potential candidate based on a separate 
proteomics analysis (unpublished data).
The aim of this study was to validate the usefulness of adding candidate biomarkers for the 
diagnosis and/or prognosis of IPS, as well as to compare their profiles to those of viral 
pneumonia.
METHODS
Study design
Among patients transplanted between 1988 and 2014 at the Fred Hutchinson Cancer 
Research Center (Fred Hutch), we identified 41 patients with IPS within 100 days after HCT 
based on radiographic findings and exclusion of occult virus or fungus infections by 
multiplex PCR assay and aspergillus galactomannan assay using frozen BAL and serum 
samples as recently reported.8 We routinely performed conventional cultures, shell viral 
culture, and direct fluorescent antibody testing to detect pathogens using BAL samples. 
Cases of viral pneumonia due to parainfluenza virus (PIV) or human rhinovirus (HRV) 
documented in BAL samples obtained within 100 days after HCT without co-pathogens 
were also selected as a comparative cohort.26,27 Transplant recipients who did not require 
bronchoscopic examination and who did not grow any bacterial or fungal blood cultures 
within 100 days after HCT were considered as unaffected controls. Patients’ demographic 
data and transplant information were retrieved from the Fred Hutch database. The study was 
approved by the Institutional Review Boards at Indiana University and Fred Hutch.
Laboratory testing
Cryopreserved plasma samples from day 7 post HCT and within one week prior to or no 
more than one day after onset of each event were analyzed. The “onset sample” for 
unaffected controls was the sample closest to day 24, which was the median day+1 of onset 
for patients with IPS. We selected six candidate proteins based on the literature and 
unpublished preliminary data, ST2, TNFR1, IL-6, LYVE, EPCR, and HVEM. ELISA was 
purchased from R&D systems (Minneapolis, USA) and a sequential ELISA workflow was 
used as previously reported.28
Statistical analysis
Logistic regression models were used to evaluate associations between each analyte in HCT 
recipients with IPS versus unaffected controls or versus those with viral pneumonia. Analyte 
concentrations were log2 transformed. Univariable models were fit using each analyte and an 
adjusted model for each analyte was constructed in a step up fashion, adding demographic 
and clinical variables to the model for each analyte and retaining those in the model if their 
inclusion modified the association of the analyte with outcome by more than 10%. Multi-
analyte models were developed to determine whether combinations of proteins improved 
discrimination between IPS patients and control cohorts. Analytes were added to the model 
in a step-up fashion, selecting the model with the lowest Akaike Information Criteria (AIC). 
The area under the curve (AUC) of the receiver operating characteristic (ROC) curve was 
evaluated for each analyte to assess its ability to discriminate between patients with IPS and 
Seo et al. Page 3
Biol Blood Marrow Transplant. Author manuscript; available in PMC 2019 April 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
controls or those with viral pneumonia. Predictive values were calculated using the 
sensitivity and specificity for the cutoff point that is closest to the top left corner of each 
ROC plane and assuming a range of prevalence values (0 to 15%) for IPS. Weighted 
versions of Kaplan-Meier survival curves were estimated for high versus low cytokine 
subgroups with a log-rank test to evaluate p-values. Since the proportion of subjects with 
IPS was far higher in our combined cohorts than would be expected in a typical HCT 
population, individuals were weighted so that subjects with IPS represented a more plausible 
8% prevalence of IPS for the survival analysis. Cox regression, among IPS patients, was 
used to assess associations between each analyte’s onset value with day 200 post-infection 
survival. Given the limited number of subjects, models were adjusted by the one clinical or 
demographic feature whose inclusion effected the greatest change (at least 10%) on the 
analyte’s association with outcome. Two-sided p values < 0.05 were considered statistically 
significant. All statistical analyses were performed using R version 3.3.2.29
RESULTS
Patient characteristics
We evaluated 41 IPS patients with cryopreserved plasma samples. As comparative cohorts, 
there were 1) 162 unaffected patients without bronchoscopic examination and any 
documented infections, and 2) 37 patients with PIV or HRV infection within 100 days after 
HCT. Characteristics of each cohort are shown in Table 1. The median onset days after HCT 
were 23 and 35 days in IPS and viral pneumonia cases, respectively. HCT recipients in 
unaffected controls included more recent HCT recipients, and peripheral blood stem cell as a 
cell source and reduced intensity conditioning were used more often among IPS or viral 
pneumonia cases than in unaffected controls. Clinical presentations in IPS and viral 
pneumonia cases are generally similar. Among the 41 IPS cases, 10 (24%) received 
corticosteroid at onset of IPS, while only 1 (2%) had corticosteroid at the time of day 7 
sample collection.
Comparison of biomarkers between IPS and controls or viral pneumonia at onset and day 
7 post-HCT
The concentrations of six candidate proteins selected based on the literature and unpublished 
preliminary data (EPCR, HVEM, IL-6, LYVE1, ST2, and TNFR1) were measured at IPS 
onset and day 7 after HCT, and are shown in Supplemental Figure 1 for each group. The 
concentrations of IL-6, ST2, and TNFR1 at onset showed trends of increasing median values 
across groups from the unaffected control to the viral pneumonia to the IPS cohorts. The 
concentrations at day 7 after HCT, which is generally before the onset of IPS (two cases 
measured within one day following diagnosis), showed similar trends for IL-6 and ST2.
Univariable logistic regression models were used to predict IPS versus unaffected controls 
and versus viral pneumonia cases based on biomarkers sampled at onset time (Table 2). IPS 
cases had significantly elevated HVEM, IL-6, LYVE1, ST2, and TNFR1 in comparison with 
unaffected controls and the same five analytes except ST2 were elevated in comparison with 
viral pneumonia cases. IL-6, ST2, and TNFR1 were significantly increased at day 7 post-
HCT for patients who will eventually develop an IPS as compared to unaffected controls, 
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and only TNFR1 was significantly elevated in IPS at day 7 in comparison to viral 
pneumonia cases. To evaluate if the biomarkers could improve our prognostic ability for IPS 
occurrence over clinical criteria only, combinations of multiple analytes was analyzed. ST2 
and IL-6 was the best combination for the comparison of IPS with controls both at onset and 
day 7 post-HCT (Table 3). On the other hand, no other marker added to the ability of 
TNFR1 to distinguish IPS from viral infections at onset of clinical signs.
We further analyzed each analyte in multivariable models that also included clinical factors 
that proved to be important in each model (Figure 1 and Supplemental Table 1). The 
adjustment variables included in each model are indicated in Figure 1. At the onset of IPS, 
HVEM (OR 2.8; p=0.001), ST2 (OR 3.8; p=0.004), and TNFR1 (OR 3.3; p=0.013) 
distinguished IPS from unaffected controls. TNFR1 (OR 3.4; p<0.001) was the major 
protein that could discriminate IPS from viral pneumonia. For prognosis at day 7 post-HCT, 
IL-6 (OR 1.4; p=0.007) and ST2 (OR 2.3; p=0.013) were discriminating best IPS from 
unaffected controls, while there was no significant marker discriminating between IPS and 
viral pneumonia at this time point.
Biomarker values as predictors for IPS
We next produced ROC curves for each biomarker without adjustment for clinical factors to 
obtain thresholds with optimized sensitivity and specificity for IPS (Figure 2). Comparing 
between IPS cases and controls, ST2 provided the highest AUC (0.89) followed by TNFR1 
(0.84) and IL-6 (0.79) at onset (Figure 2A). Cutoff values identified from the top left point 
of the ROC curve that best balance between the true positive rate and false positive rate, 
were identified as 49 ng/mL, 5113 pg/mL, and 36 pg/mL for ST2, TNFR1, and IL-6, 
respectively. At day 7 after HCT, AUC values were lower, but ST2, TNFR1, and IL-6 had 
relatively high AUC (ST2, 0.80; TNFR1, 0.68; IL-6, 0.75) and the cutoff values defined at 
the top left point of the curve are 21 ng/mL for ST2, 3421 pg/mL for TNFR1, and 61 pg/mL 
for IL-6 (Figure 2B). In distinguishing between IPS and viral pneumonia with the onset 
sample, TNFR1 (top left cutoff, 7033 pg/mL) and IL-6 (top left cutoff, 45 pg/mL) showed 
highest AUC, although they were relatively low for all the analytes (Figure 2C). Since ST2 
and IL-6 together provided the best model fit for the comparison of IPS cases with controls 
(Table 3), we calculated ROC curves based on the multiple cytokine models (Figure 3). AUC 
at onset and at day 7 after HCT were 0.91 and 0.83, respectively, which are similar to those 
provided by ST2 alone (Figure 2A and B).
Based on the cutoff values at the top left corner of the ROC curves, sensitivity and 
specificity values were determined and used in combination with a hypothetical range of IPS 
prevalence values (0 to 15%) to estimate positive and negative predictive values for each 
analyte. Positive predictive values (PPV) for IPS in comparison to unaffected controls are 
highest in ST2 followed by TNFR1 and IL-6 (Figure 4). For instance, assuming that the 
prevalence of IPS among all HCT recipients is 8%, a patient with ST2 value greater than 49 
ng/mL measured at the onset of symptoms has 50% chance of having an IPS diagnosis, a 6-
fold increase over the a priori 8% chance of identifying an IPS case. When measured at day 
7 post HCT, a patient with ST2 value greater than 21 ng/mL has a 25% chance of developing 
IPS in the near future, approximately 3-fold higher than the assumed 8% prevalence of IPS. 
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As expected in view of the low prevalence of the disease, the negative predictive values 
(NPV) were high (>90%).
Survival by biomarker level
We evaluated whether biomarkers that are related to occurrence of IPS can provide 
reasonable predictions of survival. Since the proportion of IPS cases in our cohort is much 
higher than we would expect when we combine the two populations, we down-weighted the 
IPS cases to make their contribution to the analysis more representative (8% prevalence). We 
then dichotomized the patients into high or low biomarker groups using the top left cutoff 
values from the ROC curves at day 7 after HCT and display survival curves for groups 
defined by high vs. low biomarker levels. In this hypothetical population, high IL-6 
(p<0.001) or ST2 (p=0.002) level at day 7 after HCT was significantly associated with 
higher mortality when assuming 8% IPS prevalence (Figure 5A).
Next we evaluated the prognostic value of the biomarker for mortality after IPS. Among IPS 
patients, higher levels of ST2 at onset were associated with an increased risk of death up to 
day 200 post-HCT (Hazard ratio [HR] = 1.38, p=0.028). Moderate associations were also 
seen for EPCR (HR = 1.68, p=0.065) and TNFR1 (HR = 1.65, p=0.079) (Figure 5B).
DISCUSSION
This study demonstrated that ST2, IL-6, and TNFR1 can help to make a diagnosis of IPS, 
and TNFR1 may be used to improve discrimination between IPS and respiratory viral 
pneumonia in addition to PCR assays for the different infectious agents. Importantly, 
patients with high values of both ST2 and/or IL-6 at day 7 after HCT are at high risk of 
future IPS occurrence, and ST2 and IL-6 are also associated with higher mortality.
Our proteomics analysis identified three potential biomarkers of IPS; ST2, IL-6, and 
TNFR1. ST2 and IL-6 could function as both diagnostic and prognostic markers for IPS. 
ST2 is an IL-1 receptor member and the receptor for its unique ligand: IL-33.30, 31 Recently 
it has been noted as an important biomarker of GVHD.19–25 ST2 also seems to be a 
candidate marker for diagnosis of IPS as compared to uncomplicated HCT patients. In our 
study, a formal comparison with patients developing GVHD has not been performed (see 
comment in the limitation of the study). ST2 did not discriminate IPS from viral pneumonia. 
This finding indicates that ST2 may be a marker of lung injury, which is supported by the 
previous reports that ST2 is elevated with acute lung injury and plays a role in protection of 
lung injury.14–18 Interestingly, ST2 was elevated in the early phase of HCT, suggesting that 
it is also a prognostic marker for the future development of IPS with the stronger PPV 
among the three markers elevated at day7 post-HCT. IL-6 is an inflammatory cytokine and 
has been previously shown to be elevated in patients with IPS.10, 13 Similar to ST2, IL-6 
may function as a diagnostic marker in a comparison to unaffected controls, but not viral 
pneumonia.13 It was also elevated in the early phase of HCT, although not providing as 
strong PPV as for ST2. In the multiple analyte models, the combination of ST2 and IL-6 
provided the best model fit for predicting IPS in comparison to controls both at diagnosis 
and day 7 after HCT. However, in terms of discrimination, the AUC in the combined models 
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did not increase compared to that from the models using only ST2, suggesting that it may 
not be worth the extra cost of testing for the second biomarker, IL-6.
TNFR1 is also a biomarker associated with IPS, and was the single best marker in the 
comparison with viral pneumonia. For the diagnosis of IPS, exclusion of respiratory viral 
pneumonia is critical and several obstacles such as bronchoscopic evaluation in a patient in 
poor condition or availability of comprehensive assays for respiratory viruses prevent 
accurate diagnosis of IPS. Therefore, TNFR1 as a potential marker to help distinguish IPS 
from viral pneumonia is important, although it will be necessary to validate this finding in an 
independent cohort. Etanercept, a TNFR inhibitor, is used to treat IPS and decreased TNFR1 
levels have been shown in patients who respond to etanercept.10–12
The results regarding predictive values are potentially clinically relevant. The incidence of 
IPS is low; between 5 and 10%. Based on our data, high values of ST2 or IL-6 at day 7 after 
HCT identify a subgroup with a markedly increased likelihood of IPS occurrence which 
would allow close monitoring early post-transplantation and biomarker-based preemptive 
interventions enabling personalized medicine in this more targeted population. Our 
calculation of PPV at the onset of the pulmonary symptoms showing that high ST2 has a 
PPV of approximately 50% provides an informative change in knowledge from the a priori 
likelihood of IPS based on the assumed 8% prevalence, especially when the patient cannot 
undergo bronchoscopic examination due to poor condition.
Since the incidence rate of IPS is low, approximately 8%, we carried out weighted Kaplan-
Meier estimation among controls and IPS cases to generate representative mortality 
estimates and we showed that high ST2 or IL-6 values is associated with increased mortality 
in a population with typical IPS prevalence rates. Since prevention of lung injury in the early 
phase of disease may be important to avoid mortality following IPS, early monitoring of ST2 
and IL-6 after HCT would be informative to conduct preemptive therapy. A prospective trial 
would be needed to test this hypothesis.
This study has strengths and limitations. The cohort in our study constitutes one of the 
largest available cohorts of IPS cases. Both IPS and viral pneumonia cases were extremely 
well-characterized in terms of the diagnostic panel that was applied.8, 26 For the first time in 
a biomarker study for IPS after HCT, predictive values for a range of IPS prevalence 
scenarios were estimated. This provides valuable and practical information regarding the 
degree to which knowledge about an individual’s biomarker values increases understanding 
of the likelihood of IPS for that individual, especially when patients cannot undergo 
bronchoscopic examination for diagnosis of IPS. One limitation of our study was the limited 
numbers of IPS subjects due to the low incidence of IPS and availability of samples. 
Therefore, samples were collected over a long time period, which may affect the results 
despite multivariable analyses including key clinical variables. Moreover, the number of 
subjects was insufficient to evaluate results within stratum defined by presence or absence of 
acute GVHD. Instead, we included acute GVHD as one of clinical variables in the 
multivariable analysis. Second, we evaluated PIV and HRV cases as a representative of viral 
pneumonia since the two respiratory viruses are very common in HCT recipients and the 
incidence rates of pneumonia are relatively high.32, 33 Despite of the high incidence and 
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collection from our 25-year database, the total number of the pneumonia cases with PIV or 
HRV was only 37 after several restrictions (i.e. time point after HCT, co-pathogen, and 
serum availability) and we could not evaluate the cytokine profiles separately. Viral 
pneumonia resulting from different pathogens might have a different cytokine profile. 
Therefore, TNFR1 may not be a biomarker to distinguish IPS from other viral pneumonia 
such as influenza or CMV. The third limitation is the lack of a validation cohort. 
Establishing such a cohort is difficult because the incidence rate of IPS is low, and most 
centers do not identify IPS reliably and do not have biobanked samples on these patients. 
Thus, an independent validation cohort, optimally a prospectively enrolled cohort, is 
warranted to validate our findings.
In conclusion, we identified ST2, IL-6 and TNFR1 as potential biomarkers that could help to 
screen for IPS, and TNFR1 could be a useful marker to distinguish IPS from respiratory 
viral pneumonia. ST2 and IL-6 may also function as prognostic markers of future 
occurrence of IPS. Further studies are required to validate our findings and determine the 
usefulness of these IPS candidate markers.
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Highlights
• High levels of ST2 and IL-6 in plasma distinguish IPS from uninfected 
controls.
• TNFR1 at onset was the best plasma marker to distinguish IPS from viral 
pneumonia.
• ST2 at day 7 post HCT has the highest positive predictive value for IPS 
occurrence.
• Higher level of ST2 was associated with low survival.
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Figure 1. Multivariable logistic regression models predicting IPS
Forest plots show the odds ratios for a 2-fold increase in concentration of each protein at the 
onset or day 7 after HCT from IPS cases compared to controls (upper panels) or viral 
pneumonia (lower panels). A multivariable model for each analyte was constructed in a step 
up fashion by adding clinical variables to the model that modified the association of the 
analyte with the outcome by more than 10%. Final adjustment factors included in each 
model are indicated by numbers shown in the right column of each panel, indicating 
inclusion of selected adjustment variables numbered as follows: 1. sex, 2. transplant age, 3. 
presence of acute GVHD, 4. transplant year, 5. intensity of conditioning, 6. oxygen 
requirement at the time of sampling, 7. cell source, 8. donor type.
Abbreviations: HCT, hematopoietic cell transplantation; IPS, idiopathic pneumonia 
syndrome; HRV, human rhinovirus; PIV, parainfluenza virus; EPCR, endothelial protein C 
receptor; HVEM, herpes virus entry mediator; IL-6, interleukin-6; LYVE1, lymphocyte 
vessel endothelial receptor; ST2, Stimulation 2; TNFR1, tumor necrosis factor receptor 1.
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Figure 2. ROC curves using protein concentration
(A) ROC curves of each protein comparing to controls at the onset. (B) ROC curves of each 
protein comparing to controls at day 7 post-HCT. (C) ROC curves of each protein comparing 
to viral pneumonia at the onset. The values in labels indicate TPR/FPR at each threshold; 
Green: TPR ≥ 95%, Light purple: FPR ≤ 15%, Orange: top left.
Abbreviations: ROC, receiver operating characteristic; HCT, hematopoietic cell 
transplantation; TPR, true positive rate; FPR, false positive rate; EPCR, endothelial protein 
C receptor; HVEM, herpes virus entry mediator; IL-6, interleukin-6; LYVE1, lymphocyte 
vessel endothelial receptor; ST2, Stimulation 2; TNFR1, tumor necrosis factor receptor 1.
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Figure 3. ROC curves in multiple cytokine models
ROC curves in the combination of ST2 and IL-6 comparing to controls at the onset or at day 
7 post-HCT. The values in labels indicate TPR/FPR at each threshold; Green: TPR ≥ 95%, 
Light purple: FPR ≤ 15%, Orange: top left.
Abbreviations: ROC, receiver operating characteristic; ST2, Stimulation 2; IL-6, 
interleukin-6; HCT, hematopoietic cell transplantation; TPR, true positive rate; FPR, false 
positive rate.
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Figure 4. Prognostic values by prevalence of IPS
Negative Predictive Value (NPV, left panels) and Positive Predictive Value (PPV, right 
panels) curves for each biomarker are shown for predicting IPS at the day of onset or day 7 
after HCT. Predictive values were calculated using the sensitivity and specificity values from 
the points closest to the top left corner of the ROC curves and are estimated for a range of 
hypothetical IPS prevalence values (x-axis).
Abbreviations: IPS, idiopathic pneumonia syndrome; HCT, hematopoietic cell 
transplantation; ROC, receiver operating characteristic; HRV, human rhinovirus; PIV, 
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parainfluenza virus; EPCR, endothelial protein C receptor; HVEM, herpes virus entry 
mediator; IL-6, interleukin-6; LYVE1, lymphocyte vessel endothelial receptor; ST2, 
Stimulation 2; TNFR1, tumor necrosis factor receptor 1.
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Figure 5. Overall survival according to each biomarker
(A) Weighted Kaplan-Meier survival curves were estimated among IPS cases and controls 
reweighting IPS cases so that prevalence of IPS is represented as 8%. P-values resulted from 
similarly weighted log-rank tests. The cutoff values for dichotomizing the marker values 
come from the ROC analysis comparing IPS and controls at day 7 post-HCT, and are 21 
ng/mL in ST2, 61 pg/mL in IL-6, and 3421 pg/mL in TNFR1. Numbers at risk are estimated 
from weights (below x-axis). (B) Forest plots show the associations between each analyte’s 
onset value and day 200 post-infection survival among the IPS cases. A multivariable model 
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for each analyte was constructed in a step up fashion by adding one clinical variable to the 
model that modified the association of the analyte with the outcome by more than 10%. The 
final adjustment factor included in each model is shown in the right column.
Abbreviations: IPS, idiopathic pneumonia syndrome; ROC, receiver operating characteristic; 
HCT, hematopoietic cell transplantation; ST2, Stimulation 2; IL-6, interleukin-6; TNFR1, 
tumor necrosis factor receptor 1; LYVE1, lymphocyte vessel endothelial receptor; HVEM, 
herpes virus entry mediator; EPCR, endothelial protein C receptor; Tx, transplant; O2, 
oxygen requirement at the time of sampling.
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Table 3
Multi-analyte analysis of biomarkers comparing IPS with controls or viral pneumonia
 Onset Day 7 after HCT
 Odds Ratio*
(95% CI)
 Odds Ratio*
(95% CI)
 
 P Value P Value
IPS vs Controls
 IL-6 1.4 (1.0-1.9) 0.025 1.3 (1.0-1.6) 0.066
 ST2 2.8 (2.0-4.0) <0.001 2.0 (1.5-2.8) <0.001
IPS vs PIV+HRV
 EPCR – – 0.5 (0.2-1.2) 0.12
 TNFR1 2.9 (1.5-6.0) <0.001 2.2 (1.2-4.5) 0.010
*Odds ratios represent relative odds due to a 2-fold increase in concentration of each protein.
Abbreviations: IPS, idiopathic pneumonia syndrome; HCT, hematopoietic cell transplantation; CI, confidence interval; PIV, parainfluenza virus; 
HRV, human rhinovirus
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